30th Apr 2014 14:18
LONDON (Alliance News) - Vectura Group PLC Wednesday confirmed data from Novartis AG regarding positive results from a Phase III study comparing its Utilbro Breezhaler with GlaxoSmithKline PLC's Seretide Accuhaler for the treatment of chronic obstructive pulmonary disease.
In the test Ultibro Breezhaler met both the primary and key secondary objectives, said the firm, and showed the product to have superiority over Seretide Accuhaler in terms of lung function over the first four hours post dose at the final week of the trial.
Vectura said that the safety and tolerability profile of Utilibro Breezhaler was comparable to Seretide Accuhaler.
The results will be included in Vectura's regulatory submission for the treatment in China later in the year.
Shares in Vectura were trading up 1.9% at 140.50 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L